Compass Therapeutics

Company snapshot

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’ scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required

• 15 active pipeline program(s) linked via ClinicalTrials.gov.
• 100 US patent(s) indexed to this assignee profile.
• 15 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Compass Therapeutics. Not investment advice.

• Peer + 0 momentum

  Cellectar Biosciences

  TA overlap score 23.4

• Peer + 0 momentum

  Tango Therapeutics

  TA overlap score 21.4

Recent activity

Latest pipeline, patent, and corporate events for Compass Therapeutics.

1. Jun 5, 2026 Clinical update

   Psilocybin — Phase 2

2. Jun 5, 2026 Clinical update

   Psilocybin — Phase 3

3. Jun 5, 2026 Clinical update

   CTX-10726 — Phase 1

4. May 23, 2026 Clinical update

   COMP360 psilocybin — Phase 3

5. May 23, 2026 Clinical update

   CTX-009 — Phase 3

View all clinical trial activity →

• What is Compass Therapeutics?

  Compass Therapeutics is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker CMPX. Primary therapeutic focus areas include PTSD - Post Traumatic Stress Disorder, P1b: Advanced Solid Tumors, Biliary Tract Cancer, Glioblastoma, Metastatic Colorectal C

• Is Compass Therapeutics publicly traded?

  Yes. Compass Therapeutics is listed with ticker CMPX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Compass Therapeutics develop or market?

  We link 3 drug profile(s) where Compass Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/compass-therapeutics#company-drugs.

• What are the latest developments for Compass Therapeutics?

  In the last 12 months our linked public records show 15 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Compass Therapeutics focus on?

  Compass Therapeutics focuses on PTSD - Post Traumatic Stress Disorder, P1b: Advanced Solid Tumors, Biliary Tract Cancer based on our analysis of their pipeline programs and drug development activities.